{"id":"NCT01371708","sponsor":"Pfizer","briefTitle":"A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD","officialTitle":"A 6-month, Open-label, Multi-center, Flexible Dose Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02-02","primaryCompletion":"2016-04-22","completion":"2016-04-22","firstPosted":"2011-06-13","resultsPosted":"2016-12-08","lastUpdate":"2017-07-27"},"enrollment":283,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"DVS SR","otherNames":[]}],"arms":[{"label":"Desvenlafaxine Succinate Sustained-Release","type":"EXPERIMENTAL"}],"summary":"This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).","primaryOutcome":{"measure":"Percentage of Participants With a Treatment-emergent Adverse Event (TEAE)","timeFrame":"From Week 8 (B2061032)/Day 1 (B2061030) to Week 26 of B2061030","effectByArm":[{"arm":"Placebo/DVS-SR","deltaMin":78,"sd":null},{"arm":"DVS-SR, Low Dose/DVS-SR","deltaMin":73.1,"sd":null},{"arm":"DVS-SR, High Dose/DVS-SR","deltaMin":71.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":36,"countries":["United States","Chile"]},"refs":{"pmids":["30419989"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2061030&StudyName=A%206-Month%20Extension%20Study%20To%20The%20B2061032%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20And%20Efficacy%20Of%20DVS%20SR%20In%20The%20Treatment%20Of"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":91},"commonTop":["Headache","Nausea","Nasopharyngitis","Accidental overdose","Insomnia"]}}